Amgen agrees to $200M settlement with J&J unit

Amgen will pay Johnson & Johnson's Ortho Biotech Products $200 million to end litigation involving three drugs that boost blood cells. Amgen was accused of violating antitrust laws when it offered discounts and incentives to oncology clinics for Aranesp, Neupogen and Neulasta. The company denies any wrongdoing.

View Full Article in:

Boston Globe (tiered subscription model), The · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
Washington DC, DC